PMID- 10519360
OWN - NLM
STAT- MEDLINE
DCOM- 20000225
LR  - 20220317
IS  - 0001-2815 (Print)
IS  - 0001-2815 (Linking)
VI  - 54
IP  - 3
DP  - 1999 Sep
TI  - HLA class I expression and chromosomal deletions at 6p and 15q in head and neck 
      squamous cell carcinomas.
PG  - 235-45
AB  - Loss at the chromosomal region 6p21.3 is a frequent event in head and neck 
      squamous cell carcinomas (HNSCC). Since the human leukocyte antigen (HLA) complex 
      is located at 6p21.3, loss of heterozygosity (LOH) of this region may provide 
      tumour cells with an immune-escape tumour phenotype. In the present study, we 
      have studied the correlation of HLA class I, TAP1 and TAP2 expression and LOH at 
      6p21.3. HLA class I and TAP1 and TAP2 protein expression was analysed by 
      immunohistochemical procedures. A panel of 41 HNSCC with downregulated HLA class 
      I expression was selected for LOH studies using 5 microsatellite markers located 
      at 6p21.3 (D6S105, D6S265, D6S276, D6S273, D6S291) and 2 markers located at the 
      chromosome 6 centromere (D6S473) and the 6p telomere (D6S277). In addition, LOH 
      of the beta-2-nmicroglobulin (beta2m) gene was studied using 2 microsatellite 
      markers flanking the beta2m gene (D15S126 and D15S153) and was correlated with 
      beta2m and HLA class I expression. In 20/41 (49%) of the HNSCC, allelic loss for 
      at least one locus at 6p21.3 was found. Loss at 15q was found in 4/10 (40%) HNSCC 
      with downregulated beta2m expression and in 12/41 (29%) HNSCC with downregulated 
      HLA class I expression. Our data show that downregulation of HLA class I 
      expression is correlated with loss of chromosomal regions at 6p21.3 in HNSCC. In 
      addition, LOH at 6p21.3 and 15q in 10 paired samples of DNA derived from the 
      primary HNSCC, the lymph node metastases and from peripheral blood lymphocytes 
      (PBLs) was studied. Five (5/10) primary tumours contained the same deletion as 
      the corresponding lymph node metastases. The other cases contained deletions 
      either in the primary tumour (3 cases) or in the lymph node metastases (1 case) 
      or no deletions at all (1 case).
FAU - Feenstra, M
AU  - Feenstra M
AD  - Department of Pathology, University Hospital, Utrecht, The Netherlands.
FAU - Veltkamp, M
AU  - Veltkamp M
FAU - van Kuik, J
AU  - van Kuik J
FAU - Wiertsema, S
AU  - Wiertsema S
FAU - Slootweg, P
AU  - Slootweg P
FAU - van den Tweel, J
AU  - van den Tweel J
FAU - de Weger, R
AU  - de Weger R
FAU - Tilanus, M
AU  - Tilanus M
LA  - eng
PT  - Journal Article
PL  - England
TA  - Tissue Antigens
JT  - Tissue antigens
JID - 0331072
RN  - 0 (ATP Binding Cassette Transporter, Subfamily B, Member 2)
RN  - 0 (ATP Binding Cassette Transporter, Subfamily B, Member 3)
RN  - 0 (ATP-Binding Cassette Transporters)
RN  - 0 (DNA, Neoplasm)
RN  - 0 (HLA Antigens)
RN  - 0 (HLA-A Antigens)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (TAP1 protein, human)
RN  - 0 (beta 2-Microglobulin)
RN  - 145892-13-3 (TAP2 protein, human)
SB  - IM
MH  - ATP Binding Cassette Transporter, Subfamily B, Member 2
MH  - ATP Binding Cassette Transporter, Subfamily B, Member 3
MH  - ATP-Binding Cassette Transporters/genetics
MH  - Carcinoma, Squamous Cell/chemistry/*genetics
MH  - *Chromosome Deletion
MH  - Chromosome Mapping
MH  - *Chromosomes, Human, Pair 15
MH  - *Chromosomes, Human, Pair 6
MH  - Cytoplasm/chemistry
MH  - DNA, Neoplasm
MH  - HLA Antigens/*biosynthesis
MH  - HLA-A Antigens/biosynthesis/genetics
MH  - Head and Neck Neoplasms/chemistry/*genetics
MH  - Histocompatibility Antigens Class I/*biosynthesis
MH  - Humans
MH  - Immunohistochemistry
MH  - Loss of Heterozygosity/genetics
MH  - Lymph Nodes
MH  - Lymphatic Metastasis
MH  - Major Histocompatibility Complex
MH  - Microsatellite Repeats
MH  - Trinucleotide Repeat Expansion
MH  - beta 2-Microglobulin/genetics
EDAT- 1999/10/16 09:00
MHDA- 2000/03/04 09:00
CRDT- 1999/10/16 09:00
PHST- 1999/10/16 09:00 [pubmed]
PHST- 2000/03/04 09:00 [medline]
PHST- 1999/10/16 09:00 [entrez]
AID - 10.1034/j.1399-0039.1999.540304.x [doi]
PST - ppublish
SO  - Tissue Antigens. 1999 Sep;54(3):235-45. doi: 10.1034/j.1399-0039.1999.540304.x.